A vaccine for Parkinson's disease?

Author: Chesselet, Marie-Francoise

Source: Future Neurology, Volume 1, Number 1, January 2006 , pp. 21-23(3)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Various methods for active or passive immunization are being pursued actively as potential therapies for several neurodegenerative diseases characterized by the accumulation of misfolded proteins, such as Alzheimer's and Huntington's diseases. Masliah and colleagues now provide the first evidence that this approach could also be applicable to synucleopathies, including Parkinson's disease and dementia with Lewy bodies, in which insoluble forms of α-synuclein aggregate in characteristic cytoplasmic inclusions. Although limited to mouse models, the evidence provided opens up the possibility that anti-α-synuclein antibodies may counteract the neurotoxic effects of excess α-synuclein by promoting the degradation of these aggregates. If applicable to humans, this approach could provide a way to slow down the neurodegenerative process in patients with various forms of synucleopathies, including Parkinson's disease.

Keywords: α-synuclein; antibodies; immunization; Lewy body disease; mouse models; Parkinson's disease; synucleopathies

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14796708.1.1.21

Publication date: 2006-01-01

More about this publication?

Future Neurology provides a forum to address the most important challenges and advances in our understanding of neurological disease, and highlights emerging trends and prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson's disease.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites